Investing.com - Financial Markets Worldwide

Valneva projects revenue growth and positive cashflow for 2025

Published 18/02/2025, 10:48
© Reuters.
VLS
10.56%

Investing.com -- French vaccine manufacturer Valneva (EPA:VLS) has announced its expectation for increased sales and positive cashflow in 2025.

The company's total revenue for the year is projected to be between 180 million euros and 190 million euros ($188.7 million and $199.2 million).

In addition to this, Valneva is planning to invest between 90 million and 100 million euros in research and development (R&D) within the same timeframe.

The company's revenue for the full year of 2024 saw a rise of 10%, amounting to 169.6 million euros. This growth was achieved despite the U.S. sales of its chikungunya vaccine being lower than initially expected.

As of Dec. 31, Valneva had cash and cash equivalents amounting to 168.3 million euros. The company is set to release its audited full-year results on Mar. 20.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.